VWR to Distribute Transgenomic’s ICEme Kits that Enable Liquid Biopsy-Based Cancer Research on Existing Platforms

Transgenomic’s Liquid Biopsy-Enabling ICEme Kits Will Now Be Widely Available to Researchers Across North America through VWR, Leading Global Independent Provider of Laboratory Products, Services and Solutions

Uses Ultra-Sensitive Multiplexed ICE COLD-PCR Technology that Provides Up to 500-Fold Increase in Mutation Detection with LOD to 0.01%

Customizable Kits Are Easy to Use and Work on All Downstream Sequencing Analysis Platforms

OMAHA, Neb. — Transgenomic, Inc. (NASDAQ: TBIO) today announced it has signed a non-exclusive agreement with VWR (NASDAQ: VWR) for distribution of its ICEme™ Mutation Enrichment Kits to researchers and laboratories in North America. The kits, which are based on Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) technology, are designed to facilitate genomics-based cancer research by providing accurate detection of mutations using any type of sample and any downstream sequencing platform. ICEme Kits are also custom

< | >